Received Dec 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAP | DTAP (DAPTACEL) | SANOFI PASTEUR | UNK | 4CA03C2 | OT / LL |
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
patient was only supposed to receive kinrix,patient received both daptacel and Kinrix with no reported adverse event; patient was only supposed to receive kinrix,patient received both daptacel and Kinrix with no reported adverse event; Initial information received on 05-Dec-2025 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 4 years old male patient who was supposed to receive DIPHTHERIA VACCINE TOXOID, PERTUSSIS VACCINE ACELLULAR 3-COMPONENT, POLIO VACCINE INACT 3V (VERO), TETANUS VACCINE TOXOID [KINRIX], but received both vaccine together with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included MEASLES VACCINE LIVE (ENDERS-EDMONSTON), MUMPS VACCINE LIVE (JERYL LYNN), RUBELLA VACCINE LIVE (WISTAR RA 27/3), VARICELLA ZOSTER VACCINE LIVE (OKA/MERCK) (PROQUAD) for Prophylactic vaccination (Immunisation). On 05-Dec-2025, the patient received 0.5 ml of suspect DIPHTHERIA-15/TETANUS/5 AC PERTUSSIS VACCINE, Suspension for injection (lot 4CA03C2 and expiry 31-Oct-2025 and strength unknown) via intramuscular route in the left thigh but was supposed to receive KINRIX, not produced by Sanofi Pasteur (dose, formulation, strength, lot, expiry, route and administration site: unknown) but received both vaccine together with no reported adverse event (wrong product administered) (extra dose administered) (latency same day) both for prophylactic vaccination (immunization). Action taken was not applicable for both suspects. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
PROQUAD